List view / Grid view
Researchers say their new process enables the synthesis of phenazinones, some of which have high selective toxicity for cancer cells and could be promising anticancer drugs in future.
A team has extracted single tumour cells from existing cell lines to create 3D cell cultures that could allow for personalised cancer therapies.
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
The scientists developed a therapy which uses nanobiologics to train the innate immune system to recognise and combat cancer cells.
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
A new report has said that by 2023, the flow cytometry market will be worth $8.88 billion, partly due to an increase in stem cell research.
By targeting the mutated KRAS gene, researchers have developed an experimental vaccine that protected mice against a range of cancers.
Enosi Life Science researchers Sir Marc Feldmann, Dr H Michael Shepard and Dr Fiona McCann explain why anti-TNF therapies may be effective in treating COVID-19 associated cytokine storms and other inflammatory conditions.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.
The high level of outsourcing of hit-to-lead processes will make it the fastest-growing segment of the drug discovery service market, a new report says.
Researchers show CDK8 inhibition reduces cell plasticity without damaging cells and suggest their approach could have implications for autoimmunity and oncology.
